针对性治疗在肺高血压中的比较耐受性
Magdalena Jasińska-Stroschein1, Karolina Stawarczyk1, Anna Stępień1
1Department of Biopharmacy, Medical University of Lodz, Lodz, Poland.
Archives of medical science : AMS
|February 28, 2024
概括
肺高血压治疗增加了药物不良反应 (ADR) 的风险,特别是在组合治疗方案中. 仔细监测对于使用这些治疗方法时的患者安全至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
- 医疗安全 医疗安全
背景情况:
- 肺高血压 (PH) 需要特殊的疗法.
- 了解这些治疗方法的安全概况至关重要.
研究的目的:
- 为了估计PH特定疗法的安全性概况.
- 为了比较使用安慰剂控制和活性比较试验的安全性.
主要方法:
- 对Medline,Scopus,Embase和临床试验数据库进行系统审查和元分析.
- 对严重事件,停药和药物不良反应 (ADRs) 的相对风险的评估.
- 使用医学监管活动词典 (MedRA) 分类的ADR.
主要成果:
- 在单疗法和联合疗法中,PH疗法显著增加了ADR的相对风险.
- 发红,头痛,下疼痛,四肢疼痛,肌痛和胃肠道疾病是常见的副作用.
- 组合疗法显示治疗停止的风险略高,并增加了特定副作用的发病率,如贫血和胃肠道问题.
结论:
- 大约一半的MedRA类别/亚类别的ADR显示高频率和危险比率.
- 副作用的风险在组合治疗方案中显著增加.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
165
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
181
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
181
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
166
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
166
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
157
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
157
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Pulmonary Hypertension: Classification and Pathogenesis
180
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
180


